Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169746 | 1.00 | F10 (0.51) | F10ESR2NR1H2HDAC1LMNA | |
| SCHEMBL4925164 | 0.96 | F10 (0.48) | F10ESR2NR1H2HDAC1 | |
| SCHEMBL4925170 | 0.96 | F10 (0.48) | F10ESR2NR1H2HDAC1 | |
| SCHEMBL4932105 | 0.86 | F10 (0.46) | F10ESR2NR1H2HDAC1 | |
| SCHEMBL4931150 | 0.86 | F10 (0.46) | F10ESR2NR1H2HDAC1 | |
| SCHEMBL4932110 | 0.86 | F10 (0.46) | F10ESR2NR1H2HDAC1 | |
| SCHEMBL4931162 | 0.86 | F10 (0.46) | F10ESR2NR1H2HDAC1 | |
| SCHEMBL4179365 | 0.85 | F10 (0.73) | F10 | |
| SCHEMBL4179358 | 0.85 | F10 (0.73) | F10 | |
| SCHEMBL4925123 | 0.83 | F10 (0.44) | F10ESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099231-A1 | 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors | TFPI, SERPINC1, SERPINE1 | F10 11/4885ESR2 3298/4885NR1H2 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.